



|   |  |   |
|---|--|---|
|  | <b>QMRF identifier (ECB Inventory):</b> Q8-10-14-176       |  |
|   | <b>QMRF Title:</b> QSAR for acute oral toxicity (in vitro) |   |
|   | <b>Printing Date:</b> Mar 29, 2011                         |   |

## 1. QSAR identifier

### 1.1. QSAR identifier (title):

QSAR for acute oral toxicity (in vitro)

### 1.2. Other related models:

### 1.3. Software coding the model:

QSARModel 3.5.0 Molcode Ltd., Turu 2, Tartu, 51014, Estonia <http://www.molcode.com>

## 2. General information

### 2.1. Date of QMRF:

30.08.2009

### 2.2. QMRF author(s) and contact details:

Dana Martin, Tarmo Tamm, Gunnar Karelson, Indrek Tulp, Kaido Tamm, Deniss Savchenko, Jaak Jänes, Eneli Härk, Andres Kreegipuu, Dimitar Dobchev, Mati Karelson, Molcode model development team Molcode Ltd. Turu 2, Tartu, 51014, Estonia [models@molcode.com](mailto:models@molcode.com)  
<http://www.molcode.com>

### 2.3. Date of QMRF update(s):

### 2.4. QMRF update(s):

### 2.5. Model developer(s) and contact details:

Molcode model development team Molcode Ltd Turu 2, Tartu, 51014, Estonia [models@molcode.com](mailto:models@molcode.com) <http://www.molcode.com>

### 2.6. Date of model development and/or publication:

30.08.2009

### 2.7. Reference(s) to main scientific papers and/or software package:

[1]Karelson M, Dobchev D, Tamm T, Tulp I, Jänes J, Tamm K, Lomaka A, Savchenko D & Karelson G (2008). Correlation of blood-brain penetration and human serum albumin binding with theoretical descriptors. ARKIVOC 16, 38-60.

[2]Karelson M, Karelson G, Tamm T, Tulp I, Jänes J, Tamm K, Lomaka A, Savchenko D & Dobchev D (2009). QSAR study of pharmacological permeabilities. ARKIVOC 2, 218–238.

### 2.8. Availability of information about the model:

Model is proprietary, but the training and test sets are available.

### 2.9. Availability of another QMRF for exactly the same model:

None to date

## 3. Defining the endpoint - OECD Principle 1

### 3.1. Species:

Rat and mouse

### 3.2.Endpoint:

4.Human health effects 4.2.Acute oral toxicity

### 3.3.Comment on endpoint:

### 3.4.Endpoint units:

### 3.5.Dependent variable:

$\log(\text{IC}_{50})$  - logarithm of the half maximal inhibitory concentration ( $\text{IC}_{50}$ ) in vitro. The  $\text{IC}_{50}$  indicates how much of a particular substance (inhibitor) is needed to inhibit a given biological process (or component of a process) by half.

### 3.6.Experimental protocol:

Acute oral toxicity is determined using the OECD 420 and OECD 423 (EU B.1.bis. and 1.B.tris.) test guidelines. Acute oral toxicity testing allows to obtain the information on the biologic/toxic activity of a chemical. Currently, the basis for toxicologic classification of chemicals is the median lethal dose ( $\text{LD}_{50}$ , mg/kg b.w.), which is defined as the statistically derived dose required to kill half the members of a tested population. Animals are observed individually after dosing at least once during the first 30 minutes, periodically during the first 24 hours, with special attention given during the first 4 hours, and daily thereafter, for a total of 14 days.

### 3.7.Endpoint data quality and variability:

The data were taken from Freidig et al (2001). There are 50 compounds in the dataset of the in vitro cytotoxicity (median of several  $\text{IC}_{50}$  values of different experiments) consisting of drugs, agrochemicals and industrial chemicals. The  $\text{IC}_{50}$  values of tested substances were translated to logarithmic scale ( $\log\text{IC}_{50}$ ) to reduce the range of the data

Statistics:

max value: 2.97

min value: -4.27

standard deviation: 1.90

skewness: -1.00

## 4.Defining the algorithm - OECD Principle 2

### 4.1.Type of model:

QSAR

### 4.2.Explicit algorithm:

Multilinear regression QSAR

$\text{Log}(\text{IC}_{50}) = 5.48 - 41.64 * \text{Global softness: } 1/(\text{LUMO} - \text{HOMO}) (\text{AM1}) - 1.80 * \text{Number of carbonyl groups} - 0.30 * \text{Kier\&Hall index (order 2)}$

### 4.3.Descriptors in the model:

[1]Global softness:  $1/(\text{LUMO} - \text{HOMO}) (\text{AM1})$

[2]Number of carbonyl groups

[3]Kier&Hall index (order 2)

### 4.4.Descriptor selection:

Initial pool of ~1000 descriptors. Stepwise descriptor selection based on a set of statistical selection rules:

1-parameter equations: Fisher criterion and R<sup>2</sup> over threshold, variance and t-test value over threshold, intercorrelation with another descriptor not over threshold

2 parameter equations: intercorrelation coefficient below threshold, significant correlation with endpoint in terms of correlation coefficient and t-test.

Stepwise trial of additional descriptors not significantly correlated to any already in the model.

#### **4.5. Algorithm and descriptor generation:**

1D, 2D, and 3D theoretical calculations. Quantum chemical descriptors derived from AM1 calculation. Model developed by using multilinear regression.

#### **4.6. Software name and version for descriptor generation:**

QSARModel 3.5.0

Molcode Ltd., Turu 2, Tartu, 51014, Estonia

<http://www.molcode.com>

#### **4.7. Descriptors/Chemicals ratio:**

15 (45 chemicals / 3 descriptors)

### **5. Defining the applicability domain - OECD Principle 3**

#### **5.1. Description of the applicability domain of the model:**

Applicability domain based on training set:

a) by chemical identity: diverse set of chemically reactive organic compounds (alcohols, carboxylic acids, nitriles, aromatic compounds, sulfur and phosphorous compounds, etc)

b) by descriptor value range: This model is suitable for compounds that have the descriptors in the following range:

Global softness:  $1/(\text{LUMO} - \text{HOMO})$  (AM1)(min: 0.047 , max: 0.169)

Number of carbonyl groups (min: 0 , max: 1)

Kier&Hall index (order 2) (min: 0 , max: 24.362)

#### **5.2. Method used to assess the applicability domain:**

Presence of functional groups in structures

Range of descriptor values in training set with  $\pm 30\%$  confidence

Descriptor values must fall between maximal and minimal descriptor values of training set  $\pm 30\%$

#### **5.3. Software name and version for applicability domain assessment:**

QSARModel 3.5.0

Molcode Ltd., Turu 2, Tartu, 51014, Estonia

<http://www.molcode.com>

#### **5.4. Limits of applicability:**

### **6. Internal validation - OECD Principle 4**

#### **6.1. Availability of the training set:**

Yes

#### **6.2. Available information for the training set:**

CAS RN: Yes

Chemical Name: Yes

Smiles:No

Formula:No

INChI:No

MOL file:Yes

**6.3.Data for each descriptor variable for the training set:**

All

**6.4.Data for the dependent variable for the training set:**

All

**6.5.Other information about the training set:**

45 data points: 14 negative: 31 positive values

**6.6.Pre-processing of data before modelling:**

**6.7.Statistics for goodness-of-fit:**

$R^2 = 0.85$  (Correlation coefficient);

$s = 0.59$  (Standard error of the estimate);

$F = 76.57$  (Fisher statistic);

**6.8.Robustness - Statistics obtained by leave-one-out cross-validation:**

$R^2_{cv} = 0.78$  LOO;

**6.9.Robustness - Statistics obtained by leave-many-out cross-validation:**

$R^2_{cv} = 0.83$  LMO;

**6.10.Robustness - Statistics obtained by Y-scrambling:**

**6.11.Robustness - Statistics obtained by bootstrap:**

**6.12.Robustness - Statistics obtained by other methods:**

ABC analysis (2:1 training : prediction) on sorted (in increasing order of endpoint value) data divided into 3 subsets (A;B;C). Training set formed with 2/3 of the compounds (set A+B, A+C, B+C) and validation set consisted of 1/3 of the compounds (C, B, A)

Average  $R^2$  (fitting) = 0.862

Average  $R^2$  (prediction) = 0.802

**7.External validation - OECD Principle 4**

**7.1.Availability of the external validation set:**

Yes

**7.2.Available information for the external validation set:**

CAS RN:Yes

Chemical Name:Yes

Smiles:No

Formula:No

INChI:No

MOL file:Yes

**7.3.Data for each descriptor variable for the external validation set:**

All

**7.4.Data for the dependent variable for the external validation set:**

All

### 7.5. Other information about the external validation set:

5 data points: 2 negative values: 3 positive values

### 7.6. Experimental design of test set:

The full experimental dataset was sorted according to increasing values of logIC<sub>50</sub> and each tenth compound was assigned to the test set.

### 7.7. Predictivity - Statistics obtained by external validation:

$$R^2=0.802$$

### 7.8. Predictivity - Assessment of the external validation set:

The descriptors for the test set are in the limit of applicability

### 7.9. Comments on the external validation of the model:

## 8. Providing a mechanistic interpretation - OECD Principle 5

### 8.1. Mechanistic basis of the model:

The acute oral toxicity depends on the stability and reactivity of the compound, the number of carbonyl groups and the shape of the molecule. Toxicity increases with increasing values of the descriptor Global softness:  $1/(\text{LUMO}-\text{HOMO})(\text{AM1})$ . The presence of the carbonyl group in the molecule accounts for a higher toxicity. The descriptor Kier&Hall index (order 2) shows that toxicity is also influenced by the shape and size of the molecule.

### 8.2. A priori or a posteriori mechanistic interpretation:

A posteriori mechanistic interpretation, consistent with published scientific interpretations of experiments.

### 8.3. Other information about the mechanistic interpretation:

The descriptor Global softness:  $1/(\text{LUMO} - \text{HOMO}) (\text{AM1})[1/\text{eV}]$  gives information about the reactivity and stability of the molecule. Increasing values for Global softness indicates a higher reactivity, so toxicity increases for more reactive compounds. The descriptor Number of carbonyl groups accounts for the presence of carbonyl groups in the molecule. The Kier&Hall index (order 2) gives information about different aspects of atom connectivity within a molecule, about the branching of the ring structures and the flexibility. The proposed mechanism based on the model agrees well with literature (Freidig et al, 2007).

## 9. Miscellaneous information

### 9.1. Comments:

### 9.2. Bibliography:

[1]Freidig AP, Dekkers S, Verwei M, Zvinavashe E, Bessems JGM & van de Sandt JJM (2007). Development of a QSAR for worst case estimates of acute toxicity of chemically reactive compounds. Toxicology Letters 170, 214-222.

[2]NIEHS (2001). Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity Based on Recommendations from an International Workshop Organized by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), NIH Publication No. 01-4500.

### 9.3.Supporting information:

Training set(s)

|                                |   |
|--------------------------------|---|
| Molcode acute oral training_45 | <a href="http://qsardb.jrc.it:80/qmrf/download_attachment.jsp?name=qmrf176_Molcode%20acute%20oral%20training_45.sdf">http://qsardb.jrc.it:80/qmrf/download_attachment.jsp?name=qmrf176_Molcode acute oral training_45.sdf</a> |
|--------------------------------|---|

Test set(s)

|                                |   |
|--------------------------------|---|
| OMRF_Molcode acute oral test_5 | <a href="http://qsardb.jrc.it:80/qmrf/download_attachment.jsp?name=qmrf176_OMRF_Molcode%20acute%20oral%20test_5.sdf">http://qsardb.jrc.it:80/qmrf/download_attachment.jsp?name=qmrf176_OMRF_Molcode acute oral test_5.sdf</a> |
|--------------------------------|---|

## 10.Summary (JRC QSAR Model Database)

**10.1.QMRF number:**

Q8-10-14-176

**10.2.Publication date:**

2010/02/09

**10.3.Keywords:**

Molcode, acute oral toxicity, cytotoxicity

**10.4.Comments:**